Whole physiology of liver related to drugs
Reading File
This is a broad pharmacology and physiology topic. A useful study map is:
-
Liver structure and blood supply
- Hepatic lobule, portal triad, sinusoidal blood flow
- Hepatocytes, Kupffer cells, stellate cells, bile canaliculi
- First-pass effect and hepatic extraction
-
Core liver functions affecting drugs
- Drug uptake from blood into hepatocytes
- Biotransformation, metabolism, and elimination
- Bile formation and biliary excretion
- Plasma-protein synthesis and drug binding
-
Phases of hepatic drug metabolism
- Phase I: oxidation, reduction, hydrolysis, mainly cytochrome P450 enzymes
- Phase II: conjugation, such as glucuronidation, sulfation, acetylation, glutathione conjugation
- Phase III: transporter-mediated secretion into bile or blood
-
Cytochrome P450 system
- Major isoenzymes: CYP3A4/5, CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP2E1
- Enzyme induction and inhibition
- Drug interactions and genetic variation
-
First-pass metabolism and bioavailability
- Gut-liver portal circulation
- High- versus low-extraction drugs
- Why routes such as sublingual, transdermal, and intravenous can bypass first-pass hepatic metabolism
-
Hepatic clearance and pharmacokinetics
- Hepatic blood flow
- Intrinsic metabolic capacity
- Protein binding
- Extraction ratio and the well-stirred model
- Half-life, clearance, and maintenance-dose changes
-
Biliary excretion and enterohepatic circulation
- Drug transporters, including P-glycoprotein and MRP systems
- Drugs/metabolites excreted in bile
- Intestinal reabsorption and prolonged drug action
-
Liver disease and drug dosing
- Effects of hepatitis, cirrhosis, cholestasis, and portal-systemic shunting
- Reduced metabolism, lower albumin, ascites, altered clearance
- Child-Pugh assessment and practical dose adjustment
-
Drug-induced liver injury
- Direct dose-related toxicity, such as acetaminophen overdose
- Idiosyncratic injury
- Hepatocellular, cholestatic, and mixed patterns of injury
High-level idea: The liver determines how much orally administered drug reaches systemic blood, chemically modifies many drugs into more water-soluble metabolites, excretes some compounds into bile, and produces albumin that binds many medicines. Liver blood flow, enzyme activity, transporters, and hepatic disease can therefore substantially alter a drug’s effect and toxicity.
Which section do you want in detail first: 1) metabolism phases, 2) CYP450 and interactions, 3) first-pass effect and clearance, 4) biliary excretion, or 5) liver disease and dose adjustment?
With highlated parts in picture and discuss 1-5 points except 3rd one
Reading File
Finding Sources
Finding Sources
Searching Images
liver lobule diagram portal triad central vein hepatic sinusoids bile canaliculi drug metabolism
Generating Image
An educational medical infographic showing a hepatic lobule cutaway for drug handling. Clearly label and highlight in bright yellow: portal triad, hepatic artery, portal vein, bile duct, sinusoidal blood flow toward central vein, hepatocytes, and bile canaliculi. Include simple directional arrows: orally absorbed drug from intestine enters portal vein, hepatocyte uptake and metabolism, then exits either through central vein into systemic circulation or through bile canaliculus into bile duct. Add a compact side panel labelled 'Liver functions relevant to drugs' with four highlighted numbered items: 1 Blood supply and first-pass entry, 2 Hepatocyte uptake and metabolism, 4 CYP450 drug interactions, 5 Biliary excretion and enterohepatic circulation. Exclude a section numbered 3. Accurate clean textbook anatomy, legible labels, white background.
Searching PubMed
liver drug metabolism
Searching the Web
hepatic drug metabolism CYP enzyme induction inhibition biliary excretion pharmacology overview
Liver physiology related to drugs: Points 1, 2, 4 and 5
Point 3, first-pass effect and hepatic clearance, is excluded as requested.
Reading the highlighted picture
- Portal vein: brings drug absorbed from the intestine to the liver.
- Hepatic artery: supplies oxygen-rich systemic arterial blood to hepatocytes.
- Sinusoids: low-pressure vascular channels in which blood contacts hepatocytes.
- Hepatocytes: principal cells that take up, chemically modify, store, or excrete drugs.
- Central vein: receives blood after it passes through liver sinusoids and drains it toward the systemic circulation.
- Bile canaliculi and bile duct: route by which certain drugs or metabolites are actively secreted into bile and reach the intestine.
1. Drug metabolism: Phase I and Phase II
The liver makes many lipid-soluble drugs more water-soluble so they can leave the body in urine or bile. This process is called biotransformation.
A. Phase I reactions: functionalization
These reactions expose or introduce a functional group, such as -OH, -NH₂, or -SH.
| Reaction | Main enzyme system | Example |
|---|---|---|
| Oxidation | Cytochrome P450 enzymes | Diazepam metabolism |
| Reduction | Reductases | Chloramphenicol reduction |
| Hydrolysis | Esterases/amidases | Aspirin hydrolysis |
Effects of Phase I
- May inactivate a drug.
- May produce an active metabolite. For example, codeine is partly converted to morphine by CYP2D6.
- May activate a prodrug. For example, clopidogrel needs CYP-mediated activation.
- May generate a reactive toxic metabolite. Acetaminophen can form NAPQI, normally detoxified by glutathione.
B. Phase II reactions: conjugation
The drug or its Phase I metabolite is joined to a naturally occurring molecule. This generally makes it more polar and easier to eliminate.
| Conjugation reaction | Conjugating substance | Example |
|---|---|---|
| Glucuronidation | Glucuronic acid | Morphine, bilirubin |
| Sulfation | Sulfate | Paracetamol metabolites |
| Acetylation | Acetyl-CoA | Isoniazid |
| Glutathione conjugation | Glutathione | Detoxification of NAPQI |
| Methylation | Methyl group | Some catechol compounds |
Important point: Phase II usually inactivates a drug, but exceptions exist. Morphine-6-glucuronide, for example, remains pharmacologically active.
2. Cytochrome P450 system and drug interactions
The CYP450 enzymes are mainly located in the smooth endoplasmic reticulum of hepatocytes. They account for much Phase I metabolism.
Major clinically relevant CYP enzymes
| Enzyme | Important substrates/examples | Key issue |
|---|---|---|
| CYP3A4/5 | Midazolam, simvastatin, cyclosporine, many others | Handles a large proportion of drugs |
| CYP2D6 | Codeine, metoprolol, many antidepressants | Strong genetic variability |
| CYP2C9 | Warfarin, phenytoin, NSAIDs | Interaction risk with warfarin |
| CYP2C19 | Clopidogrel, omeprazole | Influences clopidogrel activation |
| CYP1A2 | Caffeine, theophylline, clozapine | Induced by cigarette smoke |
| CYP2E1 | Ethanol, acetaminophen pathway | Produces reactive metabolites |
Enzyme inhibition
An inhibitor decreases metabolism of a substrate drug.
Result: plasma concentration and toxicity of the substrate may rise.
Examples:
- Clarithromycin or erythromycin can inhibit CYP3A.
- Azole antifungals, such as ketoconazole, can inhibit CYP3A.
- Ritonavir is a strong CYP3A inhibitor.
- Grapefruit can reduce intestinal CYP3A activity and increase exposure to some oral CYP3A substrates.
Example: clarithromycin + simvastatin can raise simvastatin concentration and increase myopathy or rhabdomyolysis risk.
Enzyme induction
An inducer increases enzyme production or activity.
Result: metabolism of the substrate increases, so its concentration and therapeutic effect may fall.
Examples:
- Rifampicin
- Carbamazepine
- Phenytoin
- Phenobarbital
- Chronic cigarette smoking, mainly through CYP1A2 induction
Example: rifampicin can reduce the effectiveness of oral contraceptives or warfarin.
The FDA maintains a practical CYP interaction table listing important substrates, inhibitors, and inducers. It defines a strong inhibitor as one that increases the AUC of a sensitive substrate by at least five-fold.
4. Biliary excretion and enterohepatic circulation
Some drugs and metabolites leave hepatocytes through the bile canaliculi rather than entering blood or urine.
Steps
- Drug is taken up from sinusoidal blood into the hepatocyte.
- It may undergo Phase I and/or Phase II metabolism.
- Transport proteins actively move it into bile canaliculi.
- Bile carries it through bile ducts to the intestine.
- It is eliminated in feces or may be reabsorbed.
Large, polar, and conjugated compounds are especially likely to undergo biliary excretion.
Important transporters
- P-glycoprotein (P-gp/MDR1): pumps several drugs out of cells.
- MRP2: exports conjugated bilirubin and drug conjugates into bile.
- BCRP: transports some drugs and metabolites into bile.
Enterohepatic circulation
A conjugated drug metabolite enters bile and the intestine. Gut bacteria may remove the conjugate. The free drug can then be reabsorbed into portal blood and return to the liver.
Clinical consequences
- Prolongs drug action and half-life.
- May produce multiple peaks in the concentration-time curve.
- Antibiotics can reduce gut bacteria and interrupt this recycling.
Examples include:
- Ethinylestradiol
- Morphine glucuronides
- Mycophenolate metabolites
- Some NSAIDs
5. Effect of liver disease on drug handling
Liver disease does not affect every medicine in the same way. The impact depends on hepatic blood flow, hepatocyte functional mass, albumin level, portosystemic shunting, biliary function, and the drug’s metabolic pathway.
Changes in cirrhosis or severe hepatic impairment
| Change | Drug-related consequence |
|---|---|
| Fewer functioning hepatocytes | Reduced metabolism of some drugs |
| Reduced hepatic blood flow | Reduced elimination of flow-dependent drugs |
| Portal-systemic shunting | More orally administered drug may escape hepatic processing |
| Low albumin | Higher free fraction of highly protein-bound drugs |
| Cholestasis | Reduced biliary excretion |
| Ascites and altered body composition | Altered volume of distribution |
| Reduced synthesis of clotting factors | Greater bleeding risk with anticoagulants |
Drugs needing particular caution
- Sedatives and opioids: may accumulate and worsen confusion or hepatic encephalopathy.
- Benzodiazepines: lorazepam, oxazepam, and temazepam are often preferred when a benzodiazepine is necessary because they mainly undergo glucuronidation.
- Warfarin: response can become unpredictable because both drug metabolism and clotting-factor synthesis are altered.
- NSAIDs: often avoided in advanced cirrhosis due to renal, bleeding, and ascites-related risks.
- Acetaminophen: can be used at reduced total daily doses in many patients with chronic liver disease, but dosing must be individualized and alcohol misuse increases risk.
- Drugs cleared in bile: accumulation may occur in cholestasis.
Practical principles
- Review all prescription, over-the-counter, herbal, and recreational substances.
- Start with a lower dose when appropriate.
- Titrate slowly and monitor effect, toxicity, liver tests, coagulation, mental state, and renal function.
- Avoid unnecessary hepatotoxic drugs and avoid multiple sedatives.
- Use formal prescribing guidance for the specific medicine rather than applying a universal dose reduction.
Recent evidence continues to highlight that susceptibility to drug-induced liver injury varies substantially among people and involves genetic and epigenetic factors, as reviewed in this 2025 systematic review.
This is a shared conversation. Sign in to Orris to start your own chat.